Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. has seen a notable rise in stock performance, with a significant increase over the past week. The company, operating in the Pharmaceuticals & Biotechnology sector, has a market capitalization of USD 1,464 million and high institutional ownership, though it faces challenges in profitability.

Intellia Therapeutics, Inc. experienced a significant gain today, outperforming the S&P 500. Despite recent challenges, including a monthly decline and financial strain reflected in cash flow and rising costs, the company maintains strong institutional support and a notable market capitalization.

Intellia Therapeutics, Inc. has faced significant stock volatility, hitting an intraday low and experiencing a substantial year-to-date decline. The company reported negative operating cash flow and a decrease in net sales, with long-term growth prospects appearing limited amid ongoing challenges in the pharmaceuticals and biotechnology sector.

Intellia Therapeutics, Inc. opened with a notable loss, reflecting a significant downturn over the past month. The company, with a market capitalization of approximately USD 1.27 billion, is currently loss-making and faces mixed technical indicators amid cautious market sentiment in the Pharmaceuticals & Biotechnology sector.

Intellia Therapeutics, Inc. saw a notable decline in stock value, contrasting with the stable performance of the S&P 500. The company has faced significant challenges, including a steep drop in operating profit and negative cash flow, while its market capitalization stands at USD 1,271 million.

Intellia Therapeutics, Inc. saw a notable increase in its stock performance on October 15, 2025, reaching an intraday high. While the company has shown impressive short-term gains and outperformed the S&P 500, it faces significant long-term financial challenges, including negative operating profit growth and low cash flow.

Intellia Therapeutics, Inc. saw a notable stock increase on October 8, 2025, reaching an intraday high of USD 26.45. The company has demonstrated impressive weekly and monthly growth, though it faces long-term challenges with a significant decline over three years and ongoing financial pressures.

Intellia Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. Despite underperforming compared to the S&P 500 over the past year, the company's market capitalization is notable. Financial metrics indicate ongoing challenges, including losses and a negative return on equity.

Intellia Therapeutics, Inc. has achieved a new 52-week high of USD 21.49, rebounding from a low of USD 5.90. Despite this milestone, the company has experienced an 11.77% decline over the past year, with a market capitalization of USD 1,271 million and ongoing financial challenges.

Intellia Therapeutics, Inc. has recently revised its evaluation amid market fluctuations, with its stock price rising to $17.26. The company has shown significant volatility over the past year, with mixed technical indicators and strong short-term returns, while facing challenges in longer-term performance metrics.

Intellia Therapeutics, Inc. has seen notable stock activity, with significant short-term gains over the past week and month, despite a longer-term decline. The company, categorized as a small-cap in the Pharmaceuticals & Biotechnology sector, faces challenges with negative return on equity and operating cash flow.

Intellia Therapeutics, Inc. has seen notable stock activity, with a significant increase on September 18, 2025. Despite recent gains and impressive short-term performance, the company faces ongoing financial challenges, including negative EBITDA and declining net sales, highlighting its complex position in the biotechnology sector.